Scientists discover genetic variant associated with prostate cancer in African Americans

Today researchers report a newly identified genetic variation that is linked to higher incidence of prostate cancer in African American men. This study, which emphasizes the importance of characterizing genetic markers associated with prostate cancer in high-risk populations, is published online in Genome Research.

Prostate cancer is the second leading cause of cancer death in men and, according to the American Cancer Society, will claim the lives of more than 27,000 men in the United States this year. Among different populations, prostate cancer exhibits significant variation in incidence rates, with African American men exhibiting the highest rate worldwide.

Recent studies investigating genetic variations associated with susceptibility to prostate cancer have implicated a specific region of chromosome 8 as harboring potential markers for the disease. In the study published today, the research groups lead by Dr. Rick Kittles of the University of Chicago and Dr. John Carpten of the Translational Genomics Research Institute further analyzed the 8q24 region of chromosome 8 by comparing the genotypes of 490 African American men diagnosed with prostate cancer and 567 control subjects. “This study took advantage of differences in genetic ancestry among the African American men in order to replicate and further localize a risk locus for prostate cancer,” says Kittles.

Using this information, the researchers characterized new genetic markers which were significantly associated with prostate cancer. “Since the prevalence of prostate cancer is almost two-fold higher among African Americans compared to European Americans, the use of ancestry informative markers for association with prostate cancer is quite powerful. We identified a novel prostate cancer risk locus that maps within a gene region on 8q24,” Kittles says. “This region contains an interesting candidate gene involved in DNA repair.”

The data gathered in this study confirmed previous investigations, indicating that common genetic variants are linked to elevated prostate cancer risk, and found even stronger effects for several of the markers on 8q24 in African Americans. These results have important implications for diagnosis and therapy. “The significance may be quite broad given the multiple genetic variants along 8q24 that impact risk,” Kittles explains. “It is likely that within the 8q24 region there is inherited predisposition to genetic instability and this is leading to increased cancer risk. By studying this region, we may be able to develop molecular targets for improved screening, early detection, and possibly treatment.”

Source: Cold Spring Harbor Laboratory

Related stories:

Prostate cancer genes behave like those in embryo
Gene activity in prostate cancer is reminiscent of that in the developing fetal prostate, providing further evidence that all cancers are not equal, Johns Hopkins researchers report. The finding could help scientists investigate how to manipulate the genetic program to fight a disease whose biology remains poorly understood despite more than half a century of investigation.
Scientists find second site for prostate cancer gene
Scientists at Wake Forest University School of Medicine and colleagues who are studying a prostate cancer gene called HNF1B have found a second independent site within the HNF1B gene on chromosome 17 (17q12) – increasing the number of genetic variants that may contribute to risk of developing the disease.
Rheb's role in cancer
Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.
Possible link found between X-rays and prostate cancer
Researchers at The University of Nottingham have shown an association between certain past diagnostic radiation procedures and an increased risk of young-onset prostate cancer — a rare form of prostate cancer which affects about 10 per cent of all men diagnosed with the disease.
Tumor-inhibiting protein could be effective in treating leukemia
(PhysOrg.com) -- Angiocidin, a tumor-inhibiting novel protein discovered by Temple University researchers, may also have a role as a new therapeutic application in treating leukemia, according to a study by the researchers.
Researchers locate and image prostate cancer as it spreads to lymph nodes
Using an engineered common cold virus, UCLA researchers delivered a genetic payload to prostate cancer cells that allowed them, using Positron Emission Tomography (PET), to locate the diseased cells as they spread to the lymph nodes, the first place prostate cancer goes before invading other organs.
Possible link found between diagnostic radiation and prostate cancer
Researchers at The University of Nottingham have shown an association between certain past diagnostic radiation procedures and an increased risk of young-onset prostate cancer — a rare form of prostate cancer which affects about 10 per cent of all men diagnosed with the disease.
UF scientists to work with German firm in prostate cancer treatment research
University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.

News discussion:

Medicine & Health news